
|Articles|January 1, 2002
Leflunomide may be option for psoriatic arthritis
SAN FRANCISCO - The disease modifying antirheumatic drug (DMARD) leflunomide (Arava), approved for use in rheumatoid arthritis, may also be an effective therapy for recalcitrant psoriatic arthritis and psoriasis, according to two new studies.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
2
Transformative Advances This Year and Beyond
3
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
4
Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO
5


















